1.	Phase I/II Study of SGN-00101 in HIV-Positive Patients With High-Grade Anal Squamous Intraepithelial Neoplasia Phase: Phase II, Phase I Type: Prevention Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: AMC-035, NCT00052897
2.	Phase II Randomized Study of SGN-00101 in Patients With Grade III Cervical Intraepithelial Neoplasia Phase: Phase II Type: Prevention Status: Completed Age: 17 and over Sponsor: NCI Protocol IDs: GOG-0197, NCT00054041
3.	Phase II Randomized Study of SGN-00101 in Patients With Grade II or III Cervical Intraepithelial Neoplasia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: BWH-000-P-CONS01, NCI-3074, NCT00060099, 3074
4.	Phase II Study of SGN-00101 Immunotherapy in Patients With Grade III Cervical Intraepithelial Neoplasia Phase: Phase II Type: Prevention Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: AECM-0309225, NCI-5850, NCT00075569, 5850
5.	A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis Phase: Phase II Type: Prevention, Treatment Status: Completed Age: 2 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: Stressgen SGN-00101-0005, SGN-00101-0005, NCT00038714
6.	Phase II Randomized Study of SGN-00101 Vaccine in Human Papillomavirus-16-Positive Patients With Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesions of the Cervix Phase: Phase II Type: Prevention Status: Closed Age: 18 to 50 Sponsor: NCI Protocol IDs: UCIRVINE-02-55, UCIRVINE-2002-2758, NCT00091130
7.	Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia Phase: Phase I Type: Prevention Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: HspE7-00101-0601, NCT00493545